Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
1. A method of maintaining serum 25-hydroxyvitamin D at a level of at least 30 ng/mL in a patient comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
2. The method of claim 1 , wherein the administration is once a day.
3. The method of claim 1 , comprising administering 1 to 100 mcg per day of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
4. The method of claim 3 , comprising administering 30 mcg of 25-hydroxyvitamin D 3 to the patient per day.
5. The method of claim 1 , comprising administering 30 mcg of 25-hydroxyvitamin D 3 daily for at least 3 weeks.
6. The method of claim 1 , wherein the sustained release formulation comprises an amount of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a range of 1 mcg to 50 mcg.
7. The method of claim 6 , wherein the sustained release formulation comprises 30 mcg of 25-hydroxyvitamin D 3 .
8. The method of claim 1 , wherein the sustained release formulation comprises the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 dispersed within a matrix comprising a release-controlling constituent.
9. The method of claim 1 , wherein the sustained release formulation comprises a lipid matrix comprising a glyceride.
10. The method of claim 1 , wherein the sustained release formulation comprises 25-hydroxyvitamin D 3 dispersed within a matrix comprising a wax and an oil.
11. The method of claim 1 , wherein the sustained release formulation further comprises a glyceride.
12. The method of claim 1 , wherein the sustained release formulation is a soft capsule.
13. The method of claim 1 , wherein the sustained release formulation comprises 25-hydroxyvitamin D 3 dispersed in a matrix comprising a wax and an oil, and a soft capsule shell.
14. A method of mitigating a surge in Vitamin D metabolism comprising administering an effective amount of a sustained release dosage formulation of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 to a patient in need of treatment thereof wherein CYP24-mediated catabolism to produce 24, 25-dihydroxyvitamin D is reduced compared to treatment with an equal dose of an immediate release composition.
15. The method of claim 14 , wherein the administration reduces the risk of hypercalciuria, hypercalcemia, and/or hyperphosphatemia compared to the immediate release composition.
16. The method of claim 14 , wherein the administration repletes blood or intracellular 25-hydroxyvitamin D levels more efficiently compared to the immediate release composition.
17. The method of claim 14 , wherein the administration avoids supraphysiologic concentrations of 25-hydroxyvitamin D 3 in the blood, cells, and/or lumen.
18. The method of claim 14 , comprising orally administering 1 mcg to 100 mcg of 25-hydroxyvitamin D 3 to the patient per day.
19. The method of claim 14 , wherein the sustained release formulation comprises 25-hydroxyvitamin D 3 dispersed in a matrix comprising a wax and an oil, and a soft capsule shell.
20. A method of reducing excessive intracellular 24-hydroxylation of 25-hydroxyvitamin D 3 comprising administering an effective amount of a sustained release dosage form of 25-hydroxyvitamin D 3 to a patient in need of treatment thereof, wherein the intracellular 24-hydroxylation of 25-hydroxyvitamin D 3 is reduced relative to treatment with an equal dose of an immediate release composition of 25-hydroxyvitamin D 3 .
21. The method of claim 1 , wherein the sustained release of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 is effected over a period of at least four hours.
22. The method of claim 21 , wherein the sustained release of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 is effected over a period of at least eight hours.
23. The method of claim 1 , wherein the sustained release formulation comprises an amount of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a range of 1 mcg to 50 mcg dispersed in a matrix comprising a wax and an oil.
24. The method of claim 1 , wherein the sustained release formulation comprises an amount of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a range of 1 mcg to 50 mcg dispersed in a matrix comprising a wax and an oil, and disposed in a soft capsule shell.